BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 22327882)

  • 1. Targeting regulatory T cells.
    Ménétrier-Caux C; Curiel T; Faget J; Manuel M; Caux C; Zou W
    Target Oncol; 2012 Mar; 7(1):15-28. PubMed ID: 22327882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines.
    Ruter J; Barnett BG; Kryczek I; Brumlik MJ; Daniel BJ; Coukos G; Zou W; Curiel TJ
    Front Biosci (Landmark Ed); 2009 Jan; 14(5):1761-70. PubMed ID: 19273160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting regulatory T cells in tumors.
    Liu C; Workman CJ; Vignali DA
    FEBS J; 2016 Jul; 283(14):2731-48. PubMed ID: 26787424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interplay of effector and regulatory T cells in cancer.
    Roychoudhuri R; Eil RL; Restifo NP
    Curr Opin Immunol; 2015 Apr; 33():101-11. PubMed ID: 25728990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Providence of the CD25
    Chakraborty S; Bhattacharjee P; Panda AK; Kajal K; Bose S; Sa G
    Immunol Cell Biol; 2018 Nov; 96(10):1035-1048. PubMed ID: 29768737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer.
    Wang RF
    Hum Immunol; 2008 Nov; 69(11):811-4. PubMed ID: 18817828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted inhibition of IL-10-secreting CD25- Treg via p38 MAPK suppression in cancer immunotherapy.
    Ohkusu-Tsukada K; Toda M; Udono H; Kawakami Y; Takahashi K
    Eur J Immunol; 2010 Apr; 40(4):1011-21. PubMed ID: 20127675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and future perspectives of T cell immunotherapy in cancer.
    de Aquino MT; Malhotra A; Mishra MK; Shanker A
    Immunol Lett; 2015 Aug; 166(2):117-33. PubMed ID: 26096822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of regulatory T cells in cancer immunity.
    Takeuchi Y; Nishikawa H
    Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pembrolizumab on CD4
    Toor SM; Sasidharan Nair V; Pfister G; Elkord E
    Clin Exp Immunol; 2019 Jun; 196(3):345-352. PubMed ID: 30693485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine.
    Kumagai S; Itahashi K; Nishikawa H
    Nat Rev Clin Oncol; 2024 May; 21(5):337-353. PubMed ID: 38424196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
    Overacre-Delgoffe AE; Vignali DAA
    Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
    Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
    J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disarming suppressor cells to improve immunotherapy.
    Whiteside TL
    Cancer Immunol Immunother; 2012 Feb; 61(2):283-288. PubMed ID: 22146892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells.
    Yaqub S; Taskén K
    Crit Rev Oncog; 2008; 14(1):57-77. PubMed ID: 19105570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of Cancer by Targeting Regulatory T cells.
    Chen BJ; Zhao JW; Zhang DH; Zheng AH; Wu GQ
    Int Immunopharmacol; 2022 Mar; 104():108469. PubMed ID: 35008005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting regulatory T-cell populations for the immunotherapy of cancer.
    van der Vliet HJ; Koon HB; Atkins MB; Balk SP; Exley MA
    J Immunother; 2007 Sep; 30(6):591-5. PubMed ID: 17667522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T regulatory cells in cancer: recent advances and therapeutic potential.
    Elkord E; Alcantar-Orozco EM; Dovedi SJ; Tran DQ; Hawkins RE; Gilham DE
    Expert Opin Biol Ther; 2010 Nov; 10(11):1573-86. PubMed ID: 20955112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells.
    Traverso I; Fenoglio D; Negrini S; Parodi A; Battaglia F; Kalli F; Conteduca G; Tardito S; Traverso P; Indiveri F; Filaci G
    Hum Immunol; 2012 Mar; 73(3):207-13. PubMed ID: 22285846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer.
    Toor SM; Elkord E
    Immunol Cell Biol; 2018 Oct; 96(9):888-897. PubMed ID: 29635843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.